Last reviewed · How we verify

NCT05936957

The Ibadan Acute and Chronic Heart Failure Project

Recruiting now Last updated 10 July 2023
What this trial tests

trial in Heart Failure in 2,000 participants. Currently enrolling.

Timeline
1 January 2015
Primary endpoint
31 December 2025
31 December 2030

Quick facts

Lead sponsorUniversity College Hospital, Ibadan
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment2,000
Start date1 January 2015
Primary completion31 December 2025
Estimated completion31 December 2030
Sites1 location across Nigeria

Conditions studied

Sponsor

University College Hospital, Ibadan

Who can join

Adults 18 to 100, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Contemporary studies from South Africa and Nigeria have built on historical reports to demonstrate that the etiology and indeed case profile of acute HF (i.e. more women and younger individuals affected in the prime of their life) is different from high-income countries. As such, HF is now responsible for 7-10% of medical admissions in the region. These are entirely based on studies on acute HF and few on chronic HF. The nexus between endemic infections such as tuberculosis (TB) and HIV/AIDS and other non-communicable or non-infectious risk factors and HF in Africa is scarcely documented. This study will assess the long-term outcomes, risk factors, clinical phenotypes, and genomics of HF in Ibadan, Nigeria, estimate catastrophic healthcare cost associated with CHF and how it affects evidence-based care; understand cultural and social conceptions of HF in the city and by extension in Nigeria. Data from each subject shall be obtained using a uniform and standardized case report forms (CRF). A detailed clinical documentation on cases of HF will be undertaken. All variables will be summarized using appropriate descriptive statistics. Means and proportions will be estimated with two-tailed 95% confidence intervals. Specified patients' outcomes will also be summarized using proportions. Factors associated wit patient outcomes will be investigated using multivariable logistic regression models. Crude and adjusted Odds Ratio (OR) with 95% confidence intervals (CI) will be estimated. The primary event outcome of the study will be mortality by cause. Secondary event outcomes will include non-fatal major events (both resulting in and not resulting in admission).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. THE IBADAN ACUTE AND CHRONIC HEART FAILURE PROJECT: RATIONALE AND DESIGN.
    Ogah OS, Obiekwe FE, Onuigbo CS, Elusiyan BD, et al · · 2025 · PMID 41858820
  2. BASELINE CLINICAL CHARACTERISTICS OF CONTEMPORARY ADULT CHRONIC RHEUMATIC HEART DISEASE IN IBADAN, NIGERIA.
    Ogah OS, Adeyanju AT, Iyawe EP, Okwunze KF, et al · · 2024 · PMID 40007716

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other University College Hospital, Ibadan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05936957.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing